FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3189148457> ?p ?o ?g. }

• W3189148457 endingPage "6364" @default.
• W3189148457 startingPage "6354" @default.
• W3189148457 abstract "Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone-sensitive prostate cancer (mHSPC). Real-world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC.In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression-free survival 1 (PFS1), and progression-free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan-Meier method and log-rank test. The Cox-proportional hazards model was used for univariate and multivariate regression analyses.Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log-rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183-0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128-0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups.AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression-free end-points." @default.
• W3189148457 created "2021-08-16" @default.
• W3189148457 creator A5002485183 @default.
• W3189148457 creator A5003645745 @default.
• W3189148457 creator A5008723176 @default.
• W3189148457 creator A5017455912 @default.
• W3189148457 creator A5020328905 @default.
• W3189148457 creator A5023266580 @default.
• W3189148457 creator A5024256452 @default.
• W3189148457 creator A5030545703 @default.
• W3189148457 creator A5038268175 @default.
• W3189148457 creator A5039277233 @default.
• W3189148457 creator A5040435638 @default.
• W3189148457 creator A5043622417 @default.
• W3189148457 creator A5052583532 @default.
• W3189148457 creator A5056479059 @default.
• W3189148457 creator A5058255705 @default.
• W3189148457 creator A5061485888 @default.
• W3189148457 creator A5062682793 @default.
• W3189148457 creator A5070418177 @default.
• W3189148457 creator A5071873488 @default.
• W3189148457 creator A5073901509 @default.
• W3189148457 creator A5082301001 @default.
• W3189148457 creator A5083483292 @default.
• W3189148457 creator A5088072625 @default.
• W3189148457 creator A5091036359 @default.
• W3189148457 date "2021-08-10" @default.
• W3189148457 modified "2023-10-13" @default.
• W3189148457 title "A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer" @default.
• W3189148457 cites W2068811106 @default.
• W3189148457 cites W2150865892 @default.
• W3189148457 cites W2620798309 @default.
• W3189148457 cites W2743350540 @default.
• W3189148457 cites W2766605453 @default.
• W3189148457 cites W2773718170 @default.
• W3189148457 cites W2787804990 @default.
• W3189148457 cites W2788160989 @default.
• W3189148457 cites W2805604514 @default.
• W3189148457 cites W2890444045 @default.
• W3189148457 cites W2894738161 @default.
• W3189148457 cites W2899353411 @default.
• W3189148457 cites W2908857416 @default.
• W3189148457 cites W2938589827 @default.
• W3189148457 cites W2947014957 @default.
• W3189148457 cites W2947893479 @default.
• W3189148457 cites W2963794755 @default.
• W3189148457 cites W2969575782 @default.
• W3189148457 cites W2970308899 @default.
• W3189148457 cites W2975895768 @default.
• W3189148457 cites W2983492159 @default.
• W3189148457 cites W2984712394 @default.
• W3189148457 cites W2988367925 @default.
• W3189148457 cites W2989485610 @default.
• W3189148457 cites W3009163421 @default.
• W3189148457 cites W3017266355 @default.
• W3189148457 cites W3034304847 @default.
• W3189148457 cites W3049539234 @default.
• W3189148457 cites W3089200753 @default.
• W3189148457 cites W3189148457 @default.
• W3189148457 doi "https://doi.org/10.1002/cam4.4184" @default.
• W3189148457 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8446402" @default.
• W3189148457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34374489" @default.
• W3189148457 hasPublicationYear "2021" @default.
• W3189148457 type Work @default.
• W3189148457 sameAs 3189148457 @default.
• W3189148457 citedByCount "5" @default.
• W3189148457 countsByYear W31891484572021 @default.
• W3189148457 countsByYear W31891484572022 @default.
• W3189148457 countsByYear W31891484572023 @default.
• W3189148457 crossrefType "journal-article" @default.
• W3189148457 hasAuthorship W3189148457A5002485183 @default.
• W3189148457 hasAuthorship W3189148457A5003645745 @default.
• W3189148457 hasAuthorship W3189148457A5008723176 @default.
• W3189148457 hasAuthorship W3189148457A5017455912 @default.
• W3189148457 hasAuthorship W3189148457A5020328905 @default.
• W3189148457 hasAuthorship W3189148457A5023266580 @default.
• W3189148457 hasAuthorship W3189148457A5024256452 @default.
• W3189148457 hasAuthorship W3189148457A5030545703 @default.
• W3189148457 hasAuthorship W3189148457A5038268175 @default.
• W3189148457 hasAuthorship W3189148457A5039277233 @default.
• W3189148457 hasAuthorship W3189148457A5040435638 @default.
• W3189148457 hasAuthorship W3189148457A5043622417 @default.
• W3189148457 hasAuthorship W3189148457A5052583532 @default.
• W3189148457 hasAuthorship W3189148457A5056479059 @default.
• W3189148457 hasAuthorship W3189148457A5058255705 @default.
• W3189148457 hasAuthorship W3189148457A5061485888 @default.
• W3189148457 hasAuthorship W3189148457A5062682793 @default.
• W3189148457 hasAuthorship W3189148457A5070418177 @default.
• W3189148457 hasAuthorship W3189148457A5071873488 @default.
• W3189148457 hasAuthorship W3189148457A5073901509 @default.
• W3189148457 hasAuthorship W3189148457A5082301001 @default.
• W3189148457 hasAuthorship W3189148457A5083483292 @default.
• W3189148457 hasAuthorship W3189148457A5088072625 @default.
• W3189148457 hasAuthorship W3189148457A5091036359 @default.
• W3189148457 hasBestOaLocation W31891484573 @default.
• W3189148457 hasConcept C121608353 @default.
• W3189148457 hasConcept C126322002 @default.
• W3189148457 hasConcept C143998085 @default.

• next